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ABSTRACT  
Obesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to 
hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are 
poorly understood. For acetaminophen (APAP), a role of hepatic cytochrome P450 2E1 
(CYP2E1) is suspected since the activity of this enzyme is consistently enhanced during NAFLD. 
The first aim of our study was to set up a cellular model of NAFLD characterized not only by 
triglyceride accumulation but also by higher CYP2E1 activity. To this end, human HepaRG cells 
were incubated for one week with stearic acid or oleic acid, in the presence of different 
concentrations of insulin. Although cellular triglycerides and the expression of lipid-responsive 
genes were similar with both fatty acids, CYP2E1 activity was significantly increased only by 
stearic acid. CYP2E1 activity was reduced by insulin and this effect was reproduced in cultured 
primary human hepatocytes. Next, APAP cytotoxicity was assessed in HepaRG cells with or 
without lipid accretion and CYP2E1 induction. Experiments with a large range of APAP 
concentrations showed that the loss of ATP and glutathione was almost always greater in the 
presence of stearic acid. In cells pretreated with the CYP2E1 inhibitor chlormethiazole, recovery 
of ATP was significantly higher in the presence of stearate with low (2.5 mM) or high (20 mM) 
concentrations of APAP. Levels of APAP-glucuronide were significantly enhanced by insulin. 
Hence, HepaRG cells can be used as a valuable model of NAFLD to unveil important metabolic 
and hormonal factors which can increase susceptibility to drug-induced hepatotoxicity.  
 
Key words: NAFLD, obesity, liver, hepatotoxicity, acetaminophen, CYP2E1 
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Introduction  
 
Liver injury can be induced by numerous drugs, herbals and industrial toxicants (Biour et al., 
2004; Seeff et al., 2015; Wahlang et al., 2013). In the most severe cases, xenobiotic-induced liver 
injury can require hospitalization and eventually lead to death of the patient (Björnsson, 2009). 
Among the different predisposing factors increasing the risk of liver injury, there is growing 
evidence that nonalcoholic fatty liver disease (NAFLD) could play a significant role (Fromenty, 
2013; Robin et al., 2005a; Tarantino et al., 2007). NAFLD is often associated with obesity and 
type 2 diabetes and encompasses a large spectrum of liver lesions including fatty liver, 
nonalcoholic steatohepatitis (NASH) and cirrhosis (Michelotti et al., 2013).  
Greater hepatotoxicity in the context of obesity and NAFLD has been documented in rodents 
and humans with some drugs, including acetaminophen (APAP), halothane and methotrexate, as 
well as other xenobiotics such as ethanol and carbon tetrachloride (Donthamsetty et al., 2007; 
Fromenty, 2013; Michaut et al., 2014; Robin et al., 2005a; Tarantino et al., 2007). However, the 
mechanisms involved in this higher susceptibility are poorly understood, although different 
hypotheses have been put forward (Fromenty, 2013). Furthermore, these mechanisms could be 
complex and different from one compound to another (Carmiel-Haggai et al., 2003; Fromenty, 
2013; Robin et al., 2005a). Notably, obesity and NAFLD in rodents and humans are associated 
with different alterations in the activity of hepatic enzymes involved in drug metabolism including 
cytochromes P450 (CYPs), UDP-glucuronosyltransferases and transporters (Brill et al., 2012; 
Canet et al., 2015). More specifically, these dysmetabolic disorders are associated with higher 
CYP2E1 activity, lower CYP3A4 activity and increased capacity of glucuronide conjugation for 
different drugs such as APAP and lorazepam  (Aubert et al., 2011; Brill et al., 2012; Chalasani et 
al., 2003; Emery et al., 2003; Kolwankar et al., 2007; Woolsey et al., 2015).  
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Deciphering the mechanisms whereby some drugs and environmental toxins are more 
hepatotoxic in the context of obesity and NAFLD requires appropriate experimental models. 
Although obese mice and rats can be useful (Aubert et al., 2011; Carmiel-Haggai et al., 2003; 
Massart et al., 2012; Robin et al., 2005a), there are numerous differences between rodents and 
humans regarding hepatic drug metabolism (Chu et al., 2013; Martignoni et al., 2006). In addition, 
investigations in animals are cumbersome and ethically problematic. Thus, a relevant human 
cellular model could be helpful in order to study hepatotoxicity in NAFLD.  
In the past few years, the metabolically competent human hepatoma HepaRG cell line has been 
shown to be a valuable model to study the mechanism of hepatotoxicity induced by drugs and 
toxicants (Anthérieu et al., 2011; McGill et al., 2011; Savary et al., 2014; Sharanek et al., 2014; 
Tobwala et al., 2015). Indeed, HepaRG cells express most of the enzymes and transcription 
factors involved in xenobiotic biotransformation and transport (Andersson et al., 2012; Aninat et 
al., 2006; Anthérieu et al., 2012). In addition, HepaRG cells have been successfully used to study 
the effects of nutrients, hormones and drugs on the expression of various enzymes involved in 
carbohydrate and lipid metabolism (Anthérieu et al., 2011; Madec et al., 2011; Nagasawa et al., 
2007; Samanez et al., 2012).  
By using HepaRG cells, the aim of the present study was two-fold. First, we sought to set up a 
cell model of NAFLD, in particular regarding the alterations of CYP2E1 and CYP3A4 activity 
that are observed in this hepatic disease. To this end, differentiated HepaRG cells were treated for 
one week with stearic acid (C18:0) or oleic acid (C18:1) in the presence of different 
concentrations of insulin. The insulin effect was investigated because previous studies suggested 
that this hormone could modulate CYP2E1 expression and activity (Ioannides et al., 1998; 
Moncion et al., 2002; Woodcroft and Novak, 1999). Second, we used this cell model of NAFLD 
in order to determine the cytotoxic effects of the painkiller APAP. Indeed, some data in rodents 
and humans suggested that NALFD could be associated with more severe APAP-induced 
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hepatotoxicity, especially after an overdose (Aubert et al., 2012; Kon et al., 2010; Michaut et al., 
2014; Myers and Shaheen, 2008; NGuyen et al., 2008). One of these rodent studies proposed that 
higher APAP hepatotoxicity in NAFLD could be attributed to greater activity of CYP2E1 (Aubert 
et al., 2012), the primary enzyme responsible for the biotransformation of APAP to the highly 
toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) (Hinson et al., 2010; McGill and 
Jaeschke, 2013). Overall, our results indicate that HepaRG cells loaded with stearic acid can be 
used as a valuable model to study the mechanisms whereby APAP is more toxic in the context of 
NAFLD.  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
Materials and methods 
 
Chemicals. 5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR), APAP, APAP-β-D-
glucuronide, APAP-sulfate, testosterone, 6β-hydroxytestosterone, chlormethiazole (CMZ), 
chlorzoxazone (CZX), metformin, dimethyl sulfoxide (DMSO), oleic acid, stearic acid, insulin 
and oil Red O were purchased from Sigma Aldrich (Saint-Quentin-Fallavier, France). William’s E 
medium was obtained from Eurobio laboratories (Les Ulis, France). Fetal Bovine Serum (FBS) 
was supplied by Lonza (Levallois-Perret, France). Glutamine, penicillin and streptomycin were 
obtained from Invitrogen (Cergy Pontoise, France). Hydrocortisone hemisuccinate was purchased 
from Upjohn Pharmacia (Guancourt, France). Protease and phosphatase inhibitors were purchased 
from Roche Diagnostics (Indianapolis, IN).  
 
Cell cultures and treatments. Native HepaRG cells were cultured as previously described (Aninat 
et al., 2006). Briefly, HepaRG cells were seeded at a density of 2.6 x 104 cells/cm2 and were first 
incubated in a William’s E medium supplemented with 10% FBS, 100 units/ml penicillin, 100 
μg/ml streptomycin, 2 mM glutamine, 5 μg/ml insulin and 50 μM hydrocortisone hemisuccinate. 
After 2 weeks, cell differentiation was induced by the same culture medium supplemented with 
2% DMSO (differentiation medium) for 2 additional weeks. Cells were subsequently treated for 1 
week with different concentrations of insulin (0, 0.01 or 5 μg/ml), stearic acid (0 or 100 ?M), or 
oleic acid (0 or 100 ?M). In some experiments, lower or higher concentrations of fatty acids were 
used. For the APAP experiments, cells were incubated with different concentrations of this drug 
(0 to 20 mM) during the last 6, 24 or 48 h of the 7-day treatment, so that untreated and APAP-
treated cells were investigated at the same time point (i.e. at day 7). Stearic acid, oleic acid and 
APAP were dissolved in DMSO whose final concentration in cultures was always set at 2%. For 
the investigations performed with the prototypical CYP2E1 inhibitor CMZ, cells were incubated 1 
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week with 150 ?M of CMZ after the end of differentiation. Whatever the treatments, the culture 
medium was renewed every 2 or 3 days during the 7-day experiments. For the experiments carried 
out with the AMP-activated protein kinase (AMPK) activators AICAR and metformin, cells were 
first preincubated for 6 h with or without 500 ?M of each activator. Cells were then treated for 24 
h with 20 mM of APAP, with or without each AMPK activator (500 ?M). HepaRG cells were 
used at passages 11 to 15. 
Primary human hepatocytes (PHH) from adult donors were prepared at Biopredic 
International (Saint-Grégoire, France) by perfusion of liver fragments provided by the Centre de 
Ressources Biologiques (CRB) Santé de Rennes. Information about the liver donors is provided in 
the Supplementary Table 1. Hepatocytes were then immediately seeded at a density of 11 x 104 
cells/cm2 in a William’s E medium supplemented with 10% FBS, 100 units/ml penicillin, 100 
μg/ml streptomycin, 2 mM glutamine, 5 μg/ml insulin and 5 μM hydrocortisone hemisuccinate. 
The medium was discarded 12 h after seeding and cells were then maintained in the same 
differentiation medium used for HepaRG cells, which was renewed every other day. Two days 
after seeding, PHH were then treated or not with oleic acid, stearic acid and insulin for one week. 
 
Oil red O staining, cellular triglycerides and apolipoprotein B in culture medium. For staining of 
neutral lipids, live cells were washed with phosphate-buffered saline, incubated for 45 min at 
room temperature with an oil red O-saturated solution, washed again, and observed under a phase-
contrast microscope. Triglyceride quantification (nmol/mg of proteins) was measured with a 
colorimetric kit purchased from Biovision (Milpitas, CA), using the manufacturer’s 
recommendations. Apolipoprotein B (apoB) levels (?g/ml) in culture medium were determined 
with the human ELISA kit purchased from Abcam (Cambridge, UK), according to the 
manufacturer’s instructions. 
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Determination of CYP2E1 and CYP3A4 activities. In order to measure CYP2E1 and CYP3A4 
activities, HepaRG cells or PHH were incubated for 6 and 2 h in phenol red-free and DMSO-free 
William’s E medium containing 300 μM CZX or 200 μM testosterone, respectively. At the end of 
the incubation, aliquots of culture media were collected and stored at -80°C until analysis. 6-
Hydroxychlorzoxazone was then quantified by high-performance liquid chromatography (HPLC)-
tandem mass spectrometry (Xenoblis, Rennes, France), whereas 6β-hydroxytestosterone was 
measured by HPLC analysis, as previously described (Aninat et al., 2006).  
 
Cellular ATP and GSH. Cellular ATP was measured with the CellTiter-Glo® assay purchased 
from Promega (Charbonnieres, France), using the manufacturer’s recommendations. Briefly, 
HepaRG cells were incubated with the reagent 10 min at 37°C and the luminescent signal was 
quantified using a POLARstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). 
Results were expressed in comparison to untreated cells. Total glutathione (GSH) was quantified 
by fluorescence with the Glutathione assay kit purchased from Cayman Chemical (Ann Arbor, 
USA), using the manufacturer’s recommendations.  
 
Assessment of APAP metabolites and APAP-protein adducts. The quantification of APAP-β-D-
glucuronide and APAP-sulfate in the cell supernatants was performed on a Thermo Scientific Q 
Exactive mass spectrometer (San Jose, CA). An HESI-II ion source was used for the electrospray 
ionization of the target compounds. Chromatographic separation of the analytes was performed 
with an Accela pump (Thermo Scientific) equipped with a Thermo Fisher Hypersil Gold C18 
column (3.0 mm, 2.1, 100 mm) as previously described (Gicquel et al., 2013). Data were acquired 
in Targeted SIM (Single Ion Monitoring) mode. For the assessment of APAP-protein adducts in 
treated HepaRG cells, APAP-cysteine was measured by using HPLC separation and 
electrochemical detection, as previously described for cultured cells (McGill et al., 2013). APAP-
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
9 
 
protein adducts result from the covalent binding of NAPQI to different cellular proteins, in 
particular at the mitochondrial level (McGill and Jaeschke, 2013; McGill et al., 2013). 
 
Isolation of RNA and real-time quantitative PCR analysis. Total RNA was extracted from ca. 106 
HepaRG cells with the SV total RNA isolation system purchased from Promega (Charbonnières-
les-Bains, France) and from ca. 600.000 PHH with RNeasy Micro kit purchased from Qiagen 
(Courtaboeuf, France). Each kit included a DNase treatment step. RNAs were reverse-transcribed 
into cDNA using the High-Capacity cDNA Archive kit purchased from Life technologies (Saint-
Aubin, France). Real-time quantitative PCR (RT-qPCR) was then performed using the SYBR 
Green PCR Master Mix on an Applied Biosystems 7900HT Fast Real-Time PCR System 
(Applied Biosystem, Woolston, UK). Expression of the human TATA box binding protein (TBP) 
was used as reference, and the 2–ΔΔCt method was used to express the relative expression of each 
selected gene. The sequences of the primers used in this study are presented in the Supplementary 
Table 2. Amplification of specific transcripts was confirmed by melting curve profiles generated 
at the end of each run.  
 
Western blot analysis. To assess the protein expression of CYP2E1 and CYP3A4 in HepaRG 
cells, proteins underwent SDS-polyacrylamide electrophoresis. Briefly, cells were lysed in a RIPA 
buffer (25 mM Tris-HCL pH 7.6, 150 mM NaCl, 1% NP40, 1% sodium deoxycholate and 0.1% 
sodium dodecyl sulfate) supplemented with protease and phosphatase inhibitors. Fifteen μg of 
proteins were then separated by electrophoresis on 4-12% gradient Bis-Tris gels (Invitrogen, 
Cergy-Pontoise, France), transferred to 0.2-?m nitrocellulose membranes (Bio-Rad, Hercules, 
CA), which were saturated in 2% BSA/TBS-T (0.2% tween in TBS) for 2 h at room temperature. 
Proteins were then immunoblotted with antibodies against CYP2E1 (Oxford Biomedical 
Research, Rochester Hills, MI), CYP3A4 (Oxford Biomedical Research), or heat-shock cognate 
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70 (HSC70) (Tebu-bio, Le Perray-en-Yvelines, France). Finally, blots were incubated with 
appropriate secondary antibodies, and protein bands were revealed by enhanced 
chemiluminescence in a Chemi-smart imager (Fisher Scientific, Illkirch, France). HSC70 was 
used to normalize protein loadings, and quantification was performed with the BIO-1D software. 
 
Statistical analysis. All results are expressed as mean ± SEM (standard error of mean). 
Comparisons between multiple groups were performed with two-way analysis of variance 
(ANOVA).  When ANOVA provided significant differences, individual means were compared 
with the post-hoc Bonferroni test. The Mann-Whitney test was used for the experiments carried 
out in cultured PHH.   
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Results 
 
Effects of stearate, oleate and insulin on lipid content, CYP2E1 and CYP3A4  
 
HepaRG cells were incubated without or with stearic acid, oleic acid and insulin for 1 week, as 
described in the Methods section. Because insulin was studied at three different concentrations (0, 
0.01 and 5 ?g/ml), nine different experimental conditions were initially studied. As expected, 
incubation of these cells with each fatty acid (100 ?M) was associated with significantly higher 
cellular triglycerides (Fig. 1A). In addition, insulin significantly decreased triglycerides in cells 
loaded with each fatty acid (Fig. 1A) and concomitantly enhanced apoB levels in the culture 
medium, although this effect was less marked in the presence of oleic acid (Fig. 1B). Hence, 
lower accumulation of cellular triglycerides induced by insulin in steatotic HepaRG cells could be 
due, at least in part, to a greater secretion of VLDL triglycerides. This is in keeping with previous 
data in rat and human indicating that insulin favors hepatic triglyceride secretion in the long-term, 
contrary to its acute effect (Bartlett and Gibbons, 1988; Reaven et al., 1967; Zammit et al., 2001). 
Assessment of total neutral lipids (Fig. 1C) was in keeping with the measurement of cellular 
triglycerides (Fig. 1A). 
Next, the activity and expression of CYP2E1 and CYP3A4 were studied in all the experimental 
conditions. CYP2E1 activity was increased by stearic acid but not by oleic acid (Fig. 1D). 
Moreover, insulin reduced CYP2E1 activity in a concentration-dependent manner in HepaRG 
cells (Fig. 1D) and this was associated with an increase of its mRNA (Fig. 1E). Insulin also 
augmented the protein levels of CYP2E1 in a concentration-dependent manner (Supplementary 
Fig. 1). In contrast, CYP3A4 activity was significantly reduced by stearic acid, without significant 
effect of insulin (Fig. 1D). The mRNA of CYP3A4 was decreased by stearic acid, especially in 
the absence of insulin (Fig. 1E). CYP3A4 protein was reduced by stearate but also by oleate in the 
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absence of insulin (Supplementary Fig. 1). Notably, the activities of both CYP2E1 and CYP3A4 
were not significantly changed after 1 week of incubation with 50 ?M of each fatty acid, or after 
48 h of incubation with 100 ?M of these fatty acids (Supplementary Fig. 2). 
 
Effects of stearate, oleate and insulin on the expression of genes responsive to lipids and insulin 
in HepaRG cells 
 
We also assessed in normal and steatotic HepaRG cells the mRNA expression of different 
genes known to be regulated by lipids, insulin or both factors as well as genes that are of potential 
interest in the context of NAFLD (Baker et al., 2010; Begriche et al., 2013; Lu et al., 2015; 
Miquilena-Colina et al., 2011; Postic and Girard, 2008; Sookoian et al., 2010; Xie et al., 2009). As 
expected, the expression of sterol regulatory element binding transcription factor 1 (SREBF1, also 
known as SREBP-1c), SREBF2, acetyl-CoA carboxylase alpha (ACACA), fatty acid synthase 
(FASN), fatty acid translocase (FAT/CD36), stearoyl-Coenzyme A desaturase 1 (SCD1) and 
glucose-6-phosphatase (G6PC) was regulated by insulin in a concentration-dependent manner, 
whereas each fatty acid had no effect (Fig. 2). Insulin also enhanced the expression of patatin-like 
phospholipase domain containing 3 (PNPLA3) (Fig. 2), in keeping with previous studies 
(Dubuquoy et al., 2011; Huang et al., 2010). Expression of pyruvate dehydrogenase kinase 4 
(PDK4), liver pyruvate kinase (PKLR), fatty acid binding protein 4 (FABP4) and apolipoprotein 
A-IV (APOA4) was regulated by fatty acids and insulin, while that of perilipin 1 (PLIN1) and 2 
(PLIN2, also known as ADFP) was regulated only by the fatty acids (Fig. 2). Whereas expression 
of aryl hydrocarbon receptor (AHR) was unchanged in the different tested conditions, CYP1A2 
expression was negatively regulated by insulin (Fig. 2), in keeping with previous investigations 
(Barker et al., 1994; Martinez-Jiménez et al., 2006). CYP1A2 mRNA levels were also 
significantly modulated by fatty acids but this effect was less pronounced compared to insulin 
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action and apparently opposite between stearate and oleate (Fig. 2). Previous investigations in 
obese individuals showed that CYP1A2 expression and activity were not significantly changed in 
simple steatosis, whereas these parameters were significantly reduced in NASH (Fisher et al., 
2009; Lake et al., 2011). Expression of pregnane X receptor (PXR also referred to as NR1I2) was 
positively regulated by insulin, and this hormone tended to enhance CYP2C9 expression (Fig. 2). 
There was no effect of fatty acids on CYP2C9 mRNA levels, in keeping with the data reported by 
Fisher et al. (2009) for simple fatty liver. Finally, expression of alcohol dehydrogenase 1A 
(ADH1A) and aldehyde dehydrogenase 1A1 (ALDH1A1) was positively regulated by insulin 
(Fig. 2). This suggested that higher expression of these enzymes in NAFLD (Baker et al., 2010) 
could be related, at least in part, to hyperinsulinemia.  
 
Effects of stearate, oleate and insulin on CYP2E1 and CYP3A4 activities and gene expression in 
cultured PHH 
 
In another series of experiments, the effects of stearic acid, oleic acid and insulin were studied 
in PHH cultured for 1 week. In the absence of fatty acids, insulin (5 ?g/ml) significantly 
decreased CYP2E1 activity with a concomitant increase in CYP2E1 mRNA levels (Fig. 3). 
Insulin also enhanced the protein levels of CYP2E1 in a concentration-dependent manner in 
cultured PHH of 3 different donors (Supplementary Fig. 3). In contrast, insulin did not change 
CYP3A4 mRNA expression and activity (Fig. 3). Importantly, insulin increased the mRNA 
expression of SREBF1, ACACA, FASN, SCD1 and PNPLA3 and reduced that of PDK4 (Fig. 3). 
Thus, when incubated without fatty acid, the effects induced by insulin were similar between 
cultured PHH and HepaRG cells. In contrast, treatment with 100 ?M of stearic acid did not 
increase CYP2E1 activity (data not shown). However, the PHH used to assess CYP2E1 activity 
(Supplementary Table 1) presented varying degrees of steatosis before their incubation with 
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stearic acid (Supplementary Fig. 4) and thus CYP2E1 activity might have already been augmented 
in these cells.  
 
APAP-induced cytotoxicity and GSH depletion in normal and steatotic HepaRG cells  
 
In order to determine APAP cytotoxicity in normal and steatotic HepaRG cells, a large range of 
APAP concentrations was selected and cellular ATP was measured after 6, 24 and 48 h of 
treatment. Whereas no significant cytotoxicity was observed for 1 mM APAP, reduced ATP 
levels were already observed with 2.5 mM although the effects greatly depended of the culture 
conditions (Supplementary Fig. 5). Indeed, the extent of APAP-induced ATP depletion was 
consistently greater in the presence of stearic acid (Fig. 4 and Supplementary Fig. 5). Moreover, 
incubation without insulin was associated with a significantly greater ATP depletion after 6 and 
24 h for 2.5 mM APAP and after 6 h for 5 mM of this drug (Fig. 4). It was noteworthy that ATP 
levels in the basal state (i.e. without APAP treatment) were significantly lower in the absence of 
insulin and were particularly reduced with stearic acid (Fig. 4). However, when the basal ATP 
levels were equally set at 100 % for the three different conditions of fatty acid incubation, APAP 
cytotoxicity remained greater in the presence of stearic acid, except in the presence of 5 ?g/ml of 
insulin after 6 h of APAP treatment (Supplementary Fig. 5). Thus, these results indicated that the 
higher ATP depletion induced by APAP in the presence of stearic acid was not a mere 
consequence of the basal cytotoxicity induced by this fatty acid. 
In the next series of investigations, cellular GSH levels were measured after a treatment with 
low (2.5 mM) and high (20 mM) APAP concentrations. These investigations were carried out 
with the three conditions of fatty acid incubation but with only two concentrations of insulin (i.e. 
0 and 5 ?g/ml). After APAP treatment, the extent of GSH depletion was generally greater in the 
presence of stearic acid (Fig. 5). A significant effect of insulin was also observed under some 
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conditions. Indeed, GSH depletion after 12 h of 2.5 mM APAP was greater in the presence of 
insulin, whereas GSH depletion after 24 h of 20 mM APAP was greater in the absence of insulin 
(Fig. 5). Basal GSH levels were not significantly different between the 6 different conditions, 
although there was a trend towards lower GSH in the presence of stearic acid (P=0.11) (Fig. 5).  
 
APAP-induced expression of oxidative stress genes in normal and steatotic HepaRG cells 
 
Oxidative stress, including induced by APAP, can secondarily increase the expression of 
different genes such as heme oxygenase 1, ?-glutamylcysteine synthase, different glutathione S-
transferases, heat shock protein 70 and tribbles pseudokinase 3 (Aubert et al., 2012; Chan et al., 
2001). Importantly, nuclear factor, erythroid 2-like 2 (NRF2, or NFE2L2) is a transcription factor 
playing a major role in the regulation of most of these genes (Chan et al., 2001; Ma and He, 
2012). Hence, the mRNA expression of these genes was assessed in HepaRG cells treated with 
2.5 or 20 mM APAP (Fig. 6). Expression of NRF2, HMOX1, TRIB3 and HSP70 was increased 
by APAP, sometimes in a dose-dependent manner. However, it was noteworthy that the 
expression of some oxidative stress genes was already induced in the basal state (i.e. in cells not 
treated with APAP), in particular when HepaRG cells were incubated with stearic acid. This was 
observed for instance with HMOX1, TRIB3 and HSP70. Moreover, we found that in the basal 
state insulin significantly increased the expression of GSTA1/2 and GSTA3. Previous studies in 
primary cultured rat hepatocytes also showed that insulin enhanced the expression of GSTA1/2 
and GSTA3/5 (Kim et al., 2006). Interestingly, the expression of these genes was significantly 
decreased after APAP treatment in cells incubated with stearic acid. The lack of clear correlations 
between mRNA levels of several NRF2 targets was probably due to the different effects of APAP, 
fatty acids and insulin on their expression, as well as possible complex interactions between these 
factors.   
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APAP-induced cytotoxicity, GSH depletion and APAP-protein adducts in normal and steatotic 
HepaRG cells treated or not with the CYP2E1 inhibitor CMZ 
 
Another series of experiments was subsequently designed in order to determine the exact role 
of CYP2E1 in APAP-induced toxicity in HepaRG cells. For this purpose, HepaRG cells were 
incubated with 150 ?M of CMZ for 1 week before APAP treatment. This protocol of CMZ 
treatment was selected because preliminary experiments showed a maximal inhibitory effect of 
CYP2E1 activity without significant cytotoxicity (data not shown).  
Because our experiments were carried out simultaneously with and without CMZ, the recovery 
of ATP in the presence of CMZ could be calculated for these experiments. ATP recovery was 
almost always observed in the different tested conditions (Fig. 7). With 2.5 mM of APAP, ATP 
recovery with CMZ was significantly higher in the presence of stearic acid after 6 and 24 h of 
APAP treatment, but no significant effect was observed regarding insulin (Fig. 7). With 20 mM of 
APAP, ATP recovery was also higher in the presence of stearic acid but only after 6 h of APAP 
treatment (Fig. 7). Moreover, ATP recovery at this time point was significantly lower in the 
presence of insulin (Fig. 7). Notably, ATP recovery in the basal state was significantly changed in 
the presence of fatty acids. In particular, ATP recovery was higher with stearic acid and lower 
with oleic acid (Fig. 7). Taken together, these results indicated that CYP2E1 was involved in the 
loss of ATP levels after APAP treatment, but also at a lesser degree in the basal state. Moreover, 
ATP loss related to CYP2E1 activity was usually higher in the presence of stearic acid.   
The effect of CMZ pretreatment on total GSH levels and APAP-protein adducts was also 
assessed in different conditions of fatty acids, insulin and APAP treatment (2.5 or 20 mM). 
Surprisingly, CMZ did not prevent the loss of total GSH after 24 h (Fig. 8), thus indicating that 
CYP2E1 was not primarily involved in GSH depletion after APAP treatment in HepaRG cells. 
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Moreover, although APAP induced the formation of APAP-protein adducts in a concentration 
dependent manner, CMZ did not prevent the generation of these adducts 6 h after APAP treatment 
(Fig. 9).   
 
APAP-glucuronide and APAP-sulfate in normal and steatotic HepaRG cells 
 
APAP-glucuronide and APAP-sulfate were measured in the culture media of normal or 
steatotic HepaRG cells treated for 1 or 6 h with 2.5 or 20 mM of APAP. Whereas APAP-sulfate 
levels were unchanged in the different conditions of culture, APAP-glucuronide levels were 
consistently higher in the presence of insulin (Fig. 10). In contrast, there was no effect of stearate 
or oleate on APAP-glucuronide levels (Fig. 10).  
 
Lack of APAP-induced activation of c-Jun N-Terminal Kinase in HepaRG cells 
 
A recent study reported that APAP-induced cell death in HepaRG cells was not associated with 
c-Jun N-terminal kinase (JNK) activation, which was assessed from 1 to 24 h after treatment (Xie 
et al., 2014). In this study, we confirmed these data and also verified that JNK was not 
phosphorylated at earlier time (i.e.15 min) after APAP treatment (data not shown). In contrast, 
JNK was found significantly phosphorylated in HepaRG cells treated by other stimuli such as 
hydrogen peroxide, tumor necrosis factor-? and glycochenodeoxycholic acid (data not shown). 
Thus, the lack of JNK activation in HepaRG cells after APAP treatment cannot be explained by a 
defect in the JNK signaling pathway.  
 
Prevention of APAP-induced cytotoxicity in HepaRG cells by activators of AMP-activated protein 
kinase  
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AMP-activated protein kinase (AMPK) is a master regulator of energy metabolism in liver, 
especially by enhancing mitochondrial fatty acid oxidation and biogenesis (Foretz and Viollet, 
2011; Hasenour et al., 2013). Interestingly, recent investigations in primary mouse hepatocytes 
showed that APAP-induced necrosis was prevented by the AMPK activator III (DHPO), thus 
suggesting a role of AMPK impairment in APAP cytotoxicity (Saberi et al., 2014). Thus, in a last 
series of investigations, we determined the effect of the prototypical AMPK activators AICAR 
and metformin on APAP-induced cytotoxicity in non-steatotic and steatotic HepaRG cells. 
Preliminary experiments allowed us to show that the expression of both phospho-AMPK and 
phospho-acetyl-CoA carboxylase (phospho-ACC) was efficiently enhanced with 500 ?M of each 
prototypical AMPK activator (data not shown). Using this concentration, both AMPK activators 
prevented the ATP depletion measured 24 h after 20 mM of APAP (Supplementary Fig. 6), 
although the ATP recovery was in general lower compared to CMZ in the same conditions of 
APAP treatment (Fig. 7). In contrast, there was almost no GSH recovery with both AMPK 
activators, excepted in HepaRG cells incubated without fatty acid and without insulin 
(Supplementary Fig. 6).  
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Discussion 
 
There is growing evidence that NAFLD can increase the risk and the severity of hepatotoxicity 
induced by some drugs and toxins (Fromenty, 2013; Robin et al., 2005a; Tarantino et al., 2007). 
However, little is known regarding the involved mechanisms, although some hypotheses have 
been proposed (Fromenty, 2013). Thus, relevant experimental models are needed to determine 
which compounds can pose a specific risk in NAFLD and to understand why they are more 
hepatotoxic in this dysmetabolic context. Since the HepaRG cell line has been shown to be a 
valuable model to study hepatotoxicity induced by drugs and toxins (Anthérieu et al., 2011; 
McGill et al., 2011; Savary et al., 2014; Sharanek et al., 2014; Tobwala et al., 2015), a first goal of 
our study was to determine whether this cell line could also be used as a pertinent model of human 
NALFD. To this end, HepaRG cells were incubated for one week in different conditions of 
incubation with stearic acid, oleic acid and insulin. The most relevant data regarding our cellular 
model of NAFLD can be summarized as followed:  
1) Incubation of HepaRG cells for one week with stearic acid was associated with higher 
CYP2E1 activity and lower CYP3A4 activity, thus reproducing data collected in patients with 
obesity and NAFLD (Aubert et al., 2011; Brill et al., 2012; Chalasani et al., 2003; Emery et al., 
2003; Kolwankar et al., 2007; Woolsey et al., 2015). In contrast, oleic acid had no effect on 
CYP2E1 and CYP3A4 activity.  
2) The slight to moderate loss of cellular ATP observed in some conditions in HepaRG cells 
not treated with APAP was, at least in part, secondary to basal CYP2E1 activity. Increased 
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activity of CYP2E1 in HepaRG cells incubated with stearic acid was associated with altered 
expression of several genes responsive to oxidative stress.  
3) Our data with different concentrations of insulin showed that CYP2E1 activity in HepaRG 
cells was negatively regulated by this hormone in a concentration-dependent manner. However, 
insulin was responsible for an increased CYP2E1 mRNA and protein expression in a 
concentration-dependent way. Notably, experiments in cultured PHH indicated that insulin also 
reduced CYP2E1 activity with a concomitant increase in CYP2E1 mRNA levels.   
Our results regarding the effects of stearic acid, oleic acid and insulin on the activity of 
CYP2E1 and CYP3A4 in HepaRG cells deserve further discussion.  
First, although different investigations consistently reported higher hepatic CYP2E1 activity in 
human NAFLD (Aubert et al., 2011; Brill et al., 2012; Chalasani et al., 2003; Emery et al., 2003), 
the exact mechanism of this induction is still unknown. CYP2E1 induction in obese individuals 
has been associated with several dysmetabolic parameters such as the degree of steatosis, 
hyperketonemia, hyperlipidemia, insulin resistance and type 2 diabetes (Chalasani et al., 2003; 
Chtioui et al., 2007; Emery et al., 2003; Lucas et al., 1998; Wang et al., 2003). Importantly, our 
study showed that despite the similar amount of cellular triglycerides, CYP2E1 activity was 
selectively enhanced when steatosis was induced by stearic acid, but not by oleic acid. Altogether, 
these data suggest that higher CYP2E1 activity in human NAFLD could depend not only on the 
degree of steatosis but also on the composition of the deposited lipids.  
Second, an important observation in this study was that insulin significantly reduced CYP2E1 
activity in HepaRG cells and PHH in a concentration-dependent manner. Hence, low insulin was 
associated with higher CYP2E1 activity. Interestingly, insulin deficiency in rodents treated with 
streptozotocin was previously associated with higher hepatic CYP2E1 activity and this induction 
was corrected by insulin therapy (Ioannides et al., 1998; Raza et al., 2004). Thus, our results could 
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also explain why higher CYP2E1 activity has been associated with insulin resistance (Chalasani et 
al., 2003), which is frequently linked to NAFLD (Begriche et al., 2013; Tilg and Moschen 2014).  
Third, insulin reduced CYP2E1 activity but increased the mRNA and protein levels of this 
CYP in both HepaRG cells and PHH. Thus, CYP2E1 activity could be regulated post-
translationally by this hormone in hepatocytes, as suggested by previous investigations (Oesch-
Bartlomovicz et al., 1998; Wauthier et al., 2006). It is also noteworthy that the positive effect of 
insulin on CYP2E1 mRNA expression in human hepatocytes is in sharp contrast with previous 
investigations carried out in rat hepatocytes (Moncion et al., 2002; Woodcroft and Novak, 1999). 
However, CYP2E1 activity was not reported in these studies. Hence, CYP2E1 expression could 
be differentially regulated by insulin between rats and humans. Further investigations in human 
hepatocytes will be needed in order to determine the transcriptional, translational and post-
translational regulation of CYP2E1 by insulin. HepaRG cells could be helpful for this purpose.  
Fourth, different studies reported lower hepatic CYP3A4 activity during NAFLFD (Brill et al., 
2012; Kolwankar et al., 2007; Patoine et al., 2013; Woolsey et al., 2015), but no mechanism has 
been proposed so far. In this study, CYP3A4 activity was reduced in HepaRG cells incubated with 
stearic acid but not with oleic acid. Interestingly, a previous study performed in PHH showed that 
a mixture of palmitic acid (C16:0) and oleic acid reduced CYP3A4 activity (Donato et al., 2006). 
Thus, CYP3A4 activity could be specifically reduced by long-chain saturated fatty acids. It will 
be interesting to determine whether oxidative stress is involved in this effect, as suggested by 
previous studies (Anthérieu et al., 2013; Gallagher et al., 1995).  
The painkiller APAP is an interesting example of a drug that could be particularly hepatotoxic 
in the context of NAFLD. Indeed, several investigations in rodents and humans reported that 
NALFD is associated with more severe APAP-induced hepatotoxicity, especially after an 
overdose (Aubert et al., 2012; Kon et al., 2010; Michaut et al., 2014; Myers and Shaheen, 2008; 
NGuyen et al., 2008). Moreover, in vitro investigations showed that steatotic rat hepatocytes in 
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primary culture were more susceptible to APAP-induced acute cytotoxicity (Kucera et al., 2012). 
Although the mechanism is still poorly understood, some data suggest a significant role of 
CYP2E1 whose activity is consistently increased in NAFLD (Aubert et al., 2011, 2012; Michaut 
et al., 2014). Thus, the second objective of our study was to assess APAP-induced toxicity in non-
steatotic and steatotic HepaRG cells.  
The most relevant data regarding APAP toxicity can be summarized as followed:  
1) Experiments with a large range of APAP concentrations (2.5 to 20 mM) showed that APAP-
induced loss of cellular ATP was almost always greater in the presence of stearic acid. In contrast, 
APAP cytotoxicity in HepaRG cells incubated with oleic acid was similar (and sometimes lower) 
to non-steatotic cells.  
2) Investigations with the prototypical CYP2E1 inhibitor CMZ indicated that the stronger 
cytotoxicity observed with 2.5 or 20 mM APAP in the presence of stearic acid could be attributed, 
at least in part, to higher CYP2E1 activity. However, the involvement of CYP2E1 in the higher 
APAP cytotoxicity observed without insulin was significant only with 20 mM APAP.  
3) Incubation of HepaRG cells without insulin was associated with lower generation of APAP-
glucuronide for low or high APAP concentrations. 
Some of these results also deserve further discussion. First, our data suggest that the risk of 
APAP-induced hepatotoxicity in NAFLD patients could depend not only on the composition of 
the deposited lipids but also on hepatic insulin signaling. Indeed, accumulation of stearic acid 
could favor APAP cytotoxicity by enhancing CYP2E1 activity, although this fatty acid could also 
increase APAP toxicity via its deleterious effects on JNK signaling and mitochondrial function 
(Malhi et al., 2006). In addition, low (i.e. impaired) insulin signaling could increase the risk of 
APAP toxicity by reducing the generation of APAP-glucuronide and enhancing the CYP2E1-
mediated biotransformation of APAP to NAPQI. Further investigations will be needed to 
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determine whether this greater risk can occur not only after APAP overdose but also with 
therapeutic doses.  
Second, it was noteworthy that pretreatment of HepaRG cells with CMZ was associated with 
significant cellular ATP recovery but this CYP2E1 inhibitor did not afford a significant protection 
regarding total GSH and APAP-protein adducts. Notably, APAP-induced cytotoxicity could be 
the consequence of the covalent binding of NAPQI to specific cellular proteins, in particular 
within the mitochondrial compartment (McGill and Jaeschke, 2013; Tirmenstein and Nelson, 
1989). In addition, several studies reported the presence of CYP2E1 in liver mitochondria, in 
particular in humans (Bansal et al., 2013; Knockaert et al., 2011). Thus, it is conceivable that 
inhibition of CYP2E1 by CMZ could have prevented APAP-induced ATP depletion by inhibiting 
the covalent binding of this drug to a small number of key mitochondrial proteins but without 
modifying the total GSH levels since the mitochondrial pool of this antioxidant represents 10 to 
15% of the whole cellular GSH reserve (Fernandez-Checa and Kaplowitz, 2005; Robin et al., 
2005b). Finally, CMZ pretreatment of HepaRG cells may not have been able to prevent the 
generation of most APAP-protein adducts and the depletion of total GSH because NAPQI is also 
generated by CYP3A4, a microsomal enzyme that has not been reported to be located in the 
mitochondrial compartment. 
Although some investigations reported that patients with NAFLD had an overall higher risk of 
severe APAP-induced liver injury (Myers and Shaheen, 2008; NGuyen et al., 2008), such risk 
may actually vary from one obese individual to another. Indeed, while some factors linked to 
obesity and fatty liver could increase the risk of APAP hepatotoxicity (e.g. higher CYP2E1 
activity, lower GSH stores and mitochondrial dysfunction), other factors could be protective (e.g. 
increased volume of distribution, lower CYP3A4 activity and higher APAP glucuronidation) 
(Michaut et al., 2014). Furthermore, the occurrence of hepatic insulin resistance during the course 
of NAFLD might play an additional role on CYP2E1 activity and APAP glucuronidation, as 
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previously discussed. Hence, the occurrence and outcome of APAP-induced liver injury in an 
obese individual with NAFLD might depend on the delicate balance between metabolic factors 
that favor hepatic cytolysis and others that are directly, or indirectly, hepatoprotective (Michaut et 
al., 2014).  
Our cellular model has some limitations. First, HepaRG cells present low basal expression and 
activity of CYP1A2 compared to primary human hepatocytes, although this CYP is highly 
inducible in the HepaRG cell line by prototypical inducers such as 3-methylcholanthrene and 
omeprazole (Anthérieu et al., 2010; Guillouzo et al., 2007). Notably, previous investigations 
suggested that CYP1A2 could play a role in APAP bioactivation and hepatotoxicity (Laine et al., 
2009; Zaher et al., 1998), although some investigations did not support a significant role for this 
CYP in vivo (Tonge et al., 1998). Hence, low basal CYP1A2 activity might modify the toxicity 
profile of APAP in HepaRG cells.  Second, our cellular model does not take into account the 
involvement of non-parenchymal cells (e.g. Kupffer and stellate cells) and factors (e.g. 
proinflammatory cytokines and adiponectin) that have a key pathophysiological role in the 
development of both NAFLD and drug-induced hepatotoxicity (Begriche et al., 2013; Hinson et 
al., 2010; Teranishi et al., 2015). Thus, rodent models of obesity can also be helpful to determine 
the mechanisms whereby some xenobiotics are more hepatotoxic in NAFLD (Aubert et al., 2012; 
Carmiel-Haggai et al., 2003; Donthamsetty et al., 2007; Kon et al., 2010).    
In conclusion, we set up a cellular model of human NAFLD which can be a valuable tool to 
gain insight regarding the mechanisms whereby this frequent hepatic disease appears to favor 
APAP-induced acute liver failure in some patients, in particular after an overdose (Michaut et al., 
2014; Myers and Shaheen, 2009; NGuyen et al., 2008). This model can also be used to test the 
effect of other drugs or toxins suspected to be more hepatotoxic in the context of obesity and 
NAFLD, especially as a consequence of CYP2E1 induction (Fromenty, 2013).  
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Legends to the figures 
 
Figure 1. Effects of 1 week of treatment with 100 ?M stearic acid (C18:0), 100 ?M oleic acid 
(C18:1) and different concentrations of insulin on cellular triglycerides, neutral lipid 
deposition, apoB levels in culture medium and mRNA activity and expression of CYP2E1 and 
CYP3A4 in HepaRG cells. (A) Cellular triglycerides. Results are means ± SEM for 5 
independent cultures, with data in duplicates for each culture. (B) ApoB levels in culture 
medium. Results are means ± SEM for 3 independent cultures. (C) Cellular lipids stained with 
oil red O. The pictures 1 to 6 (magnification x 200) are representative of the following 
conditions: 1) HepaRG cells incubated without insulin and fatty acids; 2)  HepaRG cells 
incubated without insulin and with stearic acid;  3)  HepaRG cells incubated without insulin 
and with oleic acid;  4) HepaRG cells incubated with 5 ?g/ml insulin and without fatty acids; 5) 
HepaRG cells incubated with 5 ?g/ml insulin and with stearic acid; 6) HepaRG cells incubated 
with 5 ?g/ml insulin and with oleic acid. (D) CYP2E1 and CYP3A4 activity. Results are means 
± SEM for 5 independent cultures, with data in duplicates for each culture. (E) mRNA levels of 
CYP2E1 and CYP3A4. Results are means ± SEM for 5 independent cultures, with data in 
duplicates for each culture. In panels showing bar graphs, letters F and I indicate a significant 
effect (P<0.05) of fatty acids and insulin, respectively. *Significantly different from HepaRG 
cells incubated without fatty acids and with the same condition of insulin treatment (P<0.05). 
#Significantly different from HepaRG cells incubated without insulin and with the same 
condition of fatty acid treatment (P<0.05).  
 
Figure 2. Effects in HepaRG cells of 1 week of treatment with 100 ?M stearic acid (C18:0), 
100 ?M oleic acid (C18:1) and different concentrations of insulin on the expression of 20 
different genes. Results are means ± SEM for 5 independent cultures, with data in duplicates 
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for each culture. Letters F and I indicate a significant effect (P<0.05) of fatty acids and insulin, 
respectively. FxI indicates a significant interaction between the effects of fatty acids and 
insulin. *Significantly different from HepaRG cells incubated without fatty acids and with the 
same condition of insulin treatment (P<0.05). #Significantly different from HepaRG cells 
incubated without insulin and with the same condition of fatty acid treatment (P<0.05).  
 
Figure 3. Effects of 1 week of treatment with different concentrations of insulin in cultured 
PHH. (A) CYP2E1 and CYP3A4 activity. Results are means ± SEM for 5 and 4 independent 
cultures, respectively for the activity of CYP2E1 and CYP3A4. #Significantly different from 
PHH incubated without insulin (P<0.05). (B) mRNA levels of CYP2E1 and CYP3A4. Results 
are means ± SEM for 4 independent cultures. #Significantly different from PHH incubated 
without insulin (P<0.05). (C) mRNA expression of genes responsive to insulin. Results are 
means ± SEM for 4 independent cultures. #Significantly different from PHH incubated without 
insulin (P<0.05). 
 
Figure 4. Levels of ATP in HepaRG cells treated or not with APAP. HepaRG cells were 
incubated for 1 week with different conditions of incubation with 100 ?M stearic acid (C18:0), 
100 ?M oleic acid (C18:1) and different concentrations of insulin and subsequently treated or 
not with 2.5, 5, 10 or 20 mM of APAP. ATP levels were measured 6, 24 or 48 h after APAP 
treatment. Cellular ATP levels were set at 100% in HepaRG cells incubated for 1 week without 
fatty acids and with 5 ?g/ml of insulin and not treated with APAP. Results are means ± SEM 
for 3 to 6 independent cultures, with data in duplicates for each culture. Letters F and I indicate 
a significant effect (P<0.05) of fatty acids and insulin, respectively. *Significantly different 
from HepaRG cells incubated without fatty acids and with the same condition of insulin 
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treatment (P<0.05). #Significantly different from HepaRG cells incubated without insulin and 
with the same condition of fatty acid treatment (P<0.05).  
 
Figure 5. Levels of total GSH in HepaRG cells treated or not with APAP. HepaRG cells were 
incubated for 1 week with different conditions of incubation with 100 ?M stearic acid (C18:0), 
100 ?M oleic acid (C18:1) and two concentrations of insulin and subsequently treated or not 
with 2.5 or 20 mM of APAP. Total GSH levels were measured 6, 12 or 24 h after APAP 
treatment. Results are means ± SEM for 5 independent cultures. Letters F and I indicate a 
significant effect (P<0.05) of fatty acids and insulin, respectively and ns, not significant with a 
two-way ANOVA analysis. *Significantly different from HepaRG cells incubated without fatty 
acids and with the same condition of insulin treatment (P<0.05). 
 
Figure 6. Expression of different genes involved in oxidative stress in HepaRG cells treated or 
not with APAP. HepaRG cells were incubated for 1 week with different conditions of 
incubation with 100 ?M stearic acid (C18:0), 100 ?M oleic acid (C18:1) and two 
concentrations of insulin and subsequently treated with 2.5 or 20 mM of APAP. Gene 
expression was measured 6 h after APAP treatment. Results are means ± SEM for 3-4 
independent cultures, with data in duplicates for each culture. Letters F and I indicate a 
significant effect (P<0.05) of fatty acids and insulin, respectively and ns, not significant with a 
two-way ANOVA analysis. *Significantly different from HepaRG cells incubated without fatty 
acids and with the same condition of insulin treatment (P<0.05). 
 
Figure 7. Recovery of ATP in HepaRG cells pretreated with the CYP2E1 inhibitor CMZ and 
subsequently treated with APAP. HepaRG cells were incubated for 1 week with different 
conditions of incubation with 100 ?M stearic acid (C18:0), 100 ?M oleic acid (C18:1), two 
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concentrations of insulin and 150 ?M CMZ and subsequently treated or not with 2.5 or 20 mM 
of APAP. ATP levels were measured 6, 24 or 48 h after APAP treatment. ATP recovery was 
determined by calculating the difference of ATP levels measured with and without CMZ. 
Results are means ± SEM for 3 independent cultures, with data in triplicates for each culture. 
Letters F and I indicate a significant effect (P<0.05) of fatty acids and insulin, respectively and 
ns, not significant with a two-way ANOVA analysis. *Significantly different from HepaRG 
cells incubated without fatty acids and with the same condition of insulin treatment (P<0.05). 
#Significantly different from HepaRG cells incubated without insulin and with the same 
condition of fatty acid treatment (P<0.05). 
 
Figure 8. Total GSH levels in HepaRG cells pretreated or not with the CYP2E1 inhibitor CMZ 
and subsequently treated with APAP. HepaRG cells were incubated for 1 week with different 
conditions of incubation with 100 mM stearic acid (C18:0), 100 mM oleic acid (C18:1), two 
concentrations of insulin and 150 mM CMZ and subsequently treated or not with 2.5 or 20 mM 
APAP. GSH levels were measured 24 hours after APAP treatment. Results are means ± SEM for 
5 independent cultures. Letters F and I indicate a significant effect (P<0.05) of fatty acids and 
insulin, respectively and ns, not significant with a two-way ANOVA analysis. 
 
Figure 9. APAP-protein adducts in HepaRG cells pretreated or not with the CYP2E1 inhibitor 
CMZ and subsequently treated with APAP. HepaRG cells were incubated for 1 week with 
different conditions of incubation with 100 mM stearic acid (C18:0), 100 mM oleic acid (C18:1), 
two concentrations of insulin and 150 mM CMZ and subsequently treated or not with 2.5 or 20 
mM APAP. APAP-protein adducts were measured 6 hours after APAP treatment. Results are 
means ± SEM for 3 independent cultures. The letters ns indicate that there was no significant 
effect of fatty acids or insulin with a two-way ANOVA analysis. 
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Figure 10. Concentrations of APAP-glucuronide and APAP-sulfate in the culture media of 
HepaRG cells treated with 2.5 or 20 mM of APAP. HepaRG cells were incubated for 1 week 
with different conditions of incubation with 100 ?M stearic acid (C18:0), 100 ?M oleic acid 
(C18:1) and two concentrations of insulin and subsequently treated with 2.5 or 20 mM of 
APAP. APAP-glucuronide and APAP-sulfate were measured 1 and 6 h after APAP treatment. 
Results are means ± SEM for 4 independent cultures. The letter I indicates a significant effect 
(P<0.05) of insulin, and ns, not significant with a two-way ANOVA analysis. #Significantly 
different from HepaRG cells incubated without insulin and with the same condition of fatty 
acid treatment (P<0.05). 
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